Micro
Developing
Active
Intuitive Surgical Q2 earnings up
Gaining traction — growing article coverage and momentum.
Score
0.5
Velocity
▲ 3.0
Articles
4
Sources
2
Sentiment Timeline
Event Timeline
🤖
AI Overview
What happened: Intuitive Surgical (ISRG) reported strong Q2 2026 results on July 20, with revenue up 19% YoY to $2.89B and non-GAAP EPS up 28% to $2.80. However, shares slid post-earnings as the 2026 procedure growth outlook fell short of investor expectations. ISRG guided for full-year 2026 net income of $3.25-$3.35B, below the $3.38B consensus.
Market impact: The mixed results led to a 7% drop in ISRG's stock price, impacting investors who had bet on the company's growth. The medical technology sector, particularly competitors like Medtronic (MDT) and Stryker (SYK), may face increased scrutiny on their growth prospects.
What to watch next: ISRG's Q3 2026 earnings call on October 18 will provide further clarity on procedure growth outlook. Additionally, the FDA's decision on ISRG's new da Vinci Xi system, expected in late 2026, could drive future growth and investor sentiment.
Market impact: The mixed results led to a 7% drop in ISRG's stock price, impacting investors who had bet on the company's growth. The medical technology sector, particularly competitors like Medtronic (MDT) and Stryker (SYK), may face increased scrutiny on their growth prospects.
What to watch next: ISRG's Q3 2026 earnings call on October 18 will provide further clarity on procedure growth outlook. Additionally, the FDA's decision on ISRG's new da Vinci Xi system, expected in late 2026, could drive future growth and investor sentiment.
AI Overview as of Jul 18, 2026
Timeline
Last UpdatedJul 17, 2026